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Epidermal growth factor receptor (EGFR) and tumour growth factor alpha (TGFa) are frequently overexpressed in renal cell
carcinoma (RCC) yet responses to single-agent EGFR inhibitors are uncommon. Although von Hippel–Lindau (VHL) mutations are
predominant, RCC also develops in individuals with tuberous sclerosis (TSC). Tuberous sclerosis mutations activate mammalian
target of rapamycin (mTOR) and biochemically resemble VHL alterations. We found that RCC cell lines expressed EGFR mRNA in
the near-absence of other ErbB family members. Combined EGFR and mTOR inhibition synergistically impaired growth in a VHL-
dependent manner. Iressa blocked ERK1/2 phosphorylation specifically in wt-VHL cells, whereas rapamycin inhibited phospho-RPS6
and 4E-BP1 irrespective of VHL. In contrast, phospho-AKT was resistant to these agents and MYC translation initiation (polysome
binding) was similarly unaffected unless AKT was inhibited. Primary RCCs vs cell lines contained similar amounts of phospho-ERK1/2,
much higher levels of ErbB-3, less phospho-AKT, and no evidence of phospho-RPS6, suggesting that mTOR activity was reduced. A
subset of tumours and cell lines expressed elevated eIF4E in the absence of upstream activation. Despite similar amounts of EGFR
mRNA, cell lines (vs tumours) overexpressed EGFR protein. In the paired cell lines, PRC3 and WT8, EGFR protein was elevated post-
transcriptionally in the VHL mutant and EGF-stimulated phosphorylation was prolonged. We propose that combined EGFR and
mTOR inhibitors may be useful in the subset of RCCs with wt-VHL. However, apparent differences between primary tumours and
cell lines require further investigation.
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Renal cell carcinoma (RCC) afflicts annually over 30000 indivi-
duals in North America with 12000 deaths. Approximately 70–
75% of RCCs have clear-cell morphology and one-half or more of
these have mutations or epigenetic silencing of the von Hippel–
Lindau (VHL) gene (Latif et al, 1993; Herman et al, 1994). As part
of an E3 ubiquitin ligase (VBC), VHL targets specific substrates for
polyubiquitylation and subsequent proteasome-mediated destruc-
tion with hypoxia inducible factor alpha subunits (HIFa) being the
best characterized (Kaelin, 2003). Deregulation of HIFa appears to
be essential to the disease process (Kondo et al, 2002; Maranchie
et al, 2002), although other VHL targets including fibronectin (Ohh
et al, 1998), hnRNP molecules (Pioli and Rigby, 2001) and
deubiquitinating enzymes (Li et al, 2002) may contribute.
Overexpression of the EGF receptor (EGFR) in RCC has been
recognised for some time and EGFR signalling is mitogenic for
malignant and normal renal tubular cells (Gomella et al, 1989;
Humes et al, 1991; Uhlman et al, 1995; de Paulsen et al, 2001).
TGFa, an EGFR ligand under transcriptional control by HIF, is
constitutively expressed in VHL mutant cells (Knebelmann et al,
1998; de Paulsen et al, 2001; Gunaratnam et al, 2003). These
observations have led to clinical trials of EGFR inhibitors in RCC
(Drucker et al, 2003; Motzer et al, 2003; Foon et al, 2004; Rowinsky
et al, 2004; Amato, 2005). However, as single –agents, the response
rates have been low although stable disease may be prolonged. In
contrast, the combination of EGFR and VEGF inhibitors may be
more active than either agent alone (Hidalgo, 2003).
Downstream effectors of EGFR signalling include the Ras/Raf/
MAP kinase and phosphatidyl inositol 3-OH kinase (PI3K)
pathways. PI3K signalling leads to phosphorylation and activation
of AKT, which blocks apoptosis (Thompson and Thompson, 2004),
promotes cytoplasmic sequestration of FoxO transcription factors
(Brunet et al, 1999), and activates protein translation initiation via
the mammalian target of rapamycin (mTOR) (Hay and Sonenberg,
2004). Phosphatase and tensin homolog (PTEN) mutations, which
activate AKT, have been described in RCC in association with
more aggressive disease (Kondo et al, 2001; Shin Lee et al, 2003).
Mammalian target of rapamycin (mTOR) is inhibited by the
tuberous sclerosis (TSC) complex, which, in turn, is inhibited by
AKT and patients with TSC mutations have an increased incidence
of RCC (Al-Saleem et al, 1998). Biochemically, mouse embryo
fibroblasts defective in TSC resemble RCCs with VHL mutations as
they express elevated levels of HIFa, VEGF and glycolytic proteins
(Brugarolas et al, 2003). Tuberous sclerosis mutant cells have an
exaggerated HIFa response to hypoxia, which is blocked by
treatment with rapamycin. A rapamycin prodrug, CCI-779
(Wyeth), has been examined as a single agent in RCC (Atkins
et al, 2004). The response rate was low (7%) but included one Received 31 January 2005; revised 21 April 2005; accepted 28 April 2005
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scomplete response. Rapamycin has shown additive or synergistic
activity when combined with other tyrosine kinase inhibitors such
as Gleevec and PKC412 (Mohi et al, 2004). Rapamycin also
enhances chemotherapy responses in breast cancer cell lines
(Mondesire et al, 2004) and in Myc-driven murine lymphomas
(Ruggero et al, 2004). Tumours with loss of PTEN, loss of p53 or
amplification of GLI may be particularly sensitive to rapamycin
(Hosoi et al, 1999; Louro et al, 1999; Neshat et al, 2001).
Mammalian target of rapamycin, a serine/threonine kinase,
positively affects protein translation initiation by phosphorylating
two key regulators, 4E-BP1 and p70S6 kinase (S6K1) (Hay and
Sonenberg, 2004). eIF4E binds the 50-methyl cap (
me7GpppN)
modification of mRNAs and is essential for cap-dependent
translation initiation. Unphosphorylated 4E-BP1 binds and inhibits
eIF4E. Overexpression of eIF4E can transform NIH 3T3 cells
(Lazaris-Karatzas et al, 1990) and can cause rapamycin-sensitive
murine lymphomas to become rapamycin-resistant (Ruggero et al,
2004). In contrast to inhibiting 4E-BP1 function, S6K is activated by
mTOR which leads to the phosphorylation of ribosomal protein S6
(RPS6) and increased translation of mRNAs, particularly those
encoding components of the translation machinery itself (e.g.
RPS19). Other signalling pathways also affect protein translation
initiation. For instance, ERK1/2 activation affects multiple translation
initiation components including S6K, p90 RSK, MNK and 4E-BP1,
among others (Roux and Blenis, 2004). Also, in addition to eIF4E-
mediated cap-dependent initiation, there are internal ribosome entry
sites present in several mRNAs important in RCC such as MYC,
VEGF and Cyclin D1 (Stoneley and Willis, 2004; Shi et al, 2005),
which may allow translation initiation in a cap-independent manner.
We hypothesised that the combination of an EGFR inhibitor plus
rapamycin might inhibit growth in RCC cell lines in a synergistic
manner. This proved to be correct but synergy at low drug
concentrations was only observed in cell lines with wild-type (wt)
VHL. Mechanistically, loss of ERK1/2 and RPS6 phosphorylation
following EGFR inhibition was confined to wt-VHL cells. Rapamycin
more effectively inhibited phospho-4E-BP1 and this was VHL-
independent. In contrast, neither agent inhibited phospho-AKT and
similarly, neither agent nor combination blocked MYC translation
initiation. However, blocking AKT with the PI3K inhibitor, LY-
294002, substantially downregulated the association of MYC mRNA
with ribosomes (i.e. polysome loading). Among seven parental RCC
cell lines analysed biochemically, we found one with overexpression
of eIF4E. With these results in mind, we examined a series of patient
tumours. Extracellular signal-regulated kinase (ERK) and AKT
pathways showed similar evidence for activation, although levels of
phospho-ERK were relatively much greater. One tumour contained
elevated eIF4E and several biochemical characteristics closely
matched the one cell line with eIF4E overexpression. Most tumours,
as expected, contained elevated EGFR protein compared to normal
kidney, although these levels were substantially lower than in RCC
cell lines. Interestingly, phospho-RPS6 was markedly reduced in
tumours, suggesting that mTOR activity was lower than observed in
cell lines. These preclinical findings in cell lines suggest that
combined EGFR and mTOR inhibitors may benefit a particular
subset of RCC patients but the lack of AKT inhibition potentially
limits the response. Apparent differences between primary tumours
and cell lines suggest that it would be particularly useful to examine
tumours pre- and post-treatment with phospho-specific antibodies
to ERK, AKT and RPS6 (or S6K).
METHODS
Cell lines, genotyping and patient tumours
786-O cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). Stable 786-O transfectants, WT8
(containing wt-VHL) and PRC3 (vector control), were kindly
provided by Dr William Kaelin. Additional wt-VHL transfectants,
MPR6 and MEA2, were kindly provided by Dr Robert D Burk. 786-
O cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) plus 10% fetal calf serum (FCS). WT8, PRC3, MPR6 and
MEA2 were maintained in the same medium plus 1000mgml
 1
G418. SKRC-02, SKRC-17, SKRC-39 and SKRC-45 were kindly
provided by Dr Elisabeth Stockert (Tumour Cell Bank, Memorial
Sloan-Kettering Cancer Center, New York, NY, USA) and
maintained in RPMI-1640 with 10% FCS. ACHN was grown in
McCoy’s medium with 15% FCS and KRCY was grown in RPMI-
1640 with 15% FCS. Cells were cultured under standard conditions
in a humidified 5% CO2 atmosphere. Rapamycin and LY294002
were obtained from Sigma, St. Louis, MO, USA. EGF from
Chemicon, Int., Temecula, CA, USA, while ZD-1839 was obtained
from Astra-Zeneca, Inc., Wilmington, DE, USA, through the
auspices of Dr Paul Bunn. Cell lines were confirmed to be of
independent origin by either microsatellite genotyping analysis or
VHL mutation determination using DNA sequencing. Genotyping
analysis was performed by the University of Colorado Cancer
Center DNA Sequencing & Analysis Core using the Applied
Biosystems (Foster City, CA, USA) AmpFlSTR Profiler Plus PCR
amplification kit (No. 4303326). The microsatellite genotyping
analysis was performed as indicated by the manufacturer. The
following 10 loci were examined: D3S1358, vWA, FGA, Amelogen-
in, D8S1179, D21S11, D18S551, D5S818, D13S317 and D7S820. If a
second allele (or Y chromosome in the case of Amelogenin) was
not detected, it is listed as ‘nd’. The results (i.e. allele 1/allele 2) for
each locus listed above in order are: SKRC2: 17/nd, 15/17, 20/nd,
X/nd, 8/nd, 28/30, 12/19, 12/nd, 11/nd, 9/11; SKRC12: 15/nd, 14/16,
20/22, X/nd, 13/14, 29/nd, 12/16, 11/12, 11/13, 8/9; SKRC17: 15/nd,
14/16, 22/nd, X/nd, 13/14, 30/32.2, 15/18, 11/12, 11/12, 8/12;
SKRC39: 16/nd, 17/nd, 24/nd, X/nd, 13/nd, 29/31.2, 14/15, 13/nd,
11/nd, 8/11; SKRC45: 15/nd, 15/16, 22/23, X/nd, 12/14, 27/28, 15/
nd, 12/nd, 11/12, 12/nd; ACHN: 17/nd, 16/17, 22/nd, X/nd, 12/nd,
30/nd, 16/nd, 12/nd, 12/nd, 9/11; A498: 15/nd, 18/nd, 18/20, X/nd,
13/15, 28/32, 17/nd, 11/nd, 12/nd, 10/11; CAKI2: 14/nd, 16/17, 22/
nd, X/Y, 10/nd, 27/31, 17/nd, 11/nd, 10/nd, 12/nd; KRCY: 15/nd,
17/18, 22/nd, X/nd, 14/15, 29/30.2, 14/nd, 12/13, 12/nd, 8/12; KV6:
14/nd, 16/nd, 21/22, X/nd, 12/15, 29/nd, 16/17, 12/nd, 9/13, 9/10.
Frozen sections from 12 RCC tumours and adjacent normal-
appearing kidney were processed for Western blot, genomic DNA
isolation and quantitative RT–PCR by pulverisation in liquid N2
and storage in aliquots at  801C. Pathological parameters for this
tumour cohort are provided in Table 1.
MTT assays
Microtitre plates were seeded with 2000 cells per well on day 1.
Agents and vehicle were added on day 2 and growth continued for
an additional 5 days. MTT reagent (3- (4,5-Dimethylthiazol-2-yl)-
2,5-diphenyl-tetrazolium bromide, Sigma) was then added to
400mgml
 1 and incorporated for 2–4h. Deposited dye was
solubilised with 75% isopropanol, 240mM HCl and the absorbance
measured at 490nm in a 96-well plate reader (Molecular Devices,
Inc., Sunnyvale, CA, USA). The combination index was calculated
by CALCUSYN (Chou and Talalay, 1984).
Primers for real-time RT–PCR and VHL sequencing
RNA isolation, cDNA synthesis and quantitative RT–PCR assays
were performed as previously described (Drabkin et al, 2002).
Primer sequences (50–30) were: EGFR (for) AGATGGAGGAA
GACGGCGTC, (rev) GGAGTCACCCCTAAATGCCAC; ErbB-2 (for)
ACCTACCTGCCCACCAATGC, (rev) GGTGGTATTGTTCAGCGG
GTC; ErbB-3 (for) TCCGCTTGACTCAGCTCACC, (rev) CCCTTGC
AAACCTCATGACAG; ErbB-4 (for) CCAGCCCAGCGATTCTCAG,
(rev) AAGGAGAGGTCCCGGTTGTG; RPS19 (for) CCTCAAAAA
GTCCGGGAAGC, (rev) TGGAAGCAGCTCGCGTGTAG; b-actin
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GATGG; MYC (for), ACACCCTTCTCCCTTCGGG, (rev) AGCCGC
TCCACATACAGTCC; VEGF (for) CAAGACAAGAAAATCCCTGT
GG, (rev) CCTCGGCTTGTCACATCTG; GAPDH (for) TGCACCAC
CAACTGCTTAGC, (rev) GGCATGGACTGTGGTCATGAG; VHL (for)
GGACACACGATGGGCTTCTG, (rev) CAACCTGGAGGCATCGCTC.
Primers used for genomic amplification of VHL were: either PF1
(upstream of promoter): ACTTTATAAGCGTGATGATTGGGTG or
Exon 1 (for): CGAAGACTACGGAGGTCGACTC, (rev) CGTGCTAT
CGTCCCTGCT; Exon 2 (for) GGATTTAGAGCTTTAAGTACGC
GCTC, (rev) TGGATACCGTGCCTGACATCA; Exon 3 (for): GTTG
TTGGCAAAGCCTCTTGTTC, (rev) CCATCAAAAGCTGAGATGA
AAC. Amplification products were treated with ExoSAP-IT (USB
Corporation, Cleveland, OH, USA, 1ml/10ml PCR reaction for
30min at371C followed by 45min at 801C) to remove excess
primers and dNTPs. The products were sequenced using ABI
Prism BigDye terminators version 1.1 on an ABI 3730 automated
DNA sequencer. Sequencing of VHL Exon 2 utilised the primer
CAGGACGGTCTTGATCTCCTG together with VHL Exon 2 (rev).
Western blots
Protein lysates were prepared in ice-cold buffer containing 25mM
Tris-HCl (pH 7.2), 150mM NaCl, 5mM DTT, 2mM MgCl2, 0.5%
NP-40, 1mM PMSF, 5mgml
 1 aprotinin, 5mgml
 1 leupeptin, 1mgml
 1
pepstatin A, 1mM 1,10-phenanthroline, 10mM N-ethylmaleimide,
1m M activated Na-orthovanadate and 1mM NaF, clarified in a
microcentrifuge (5min at 10K RPM), and protein concentrations
measured by the Bradford assay. Samples were denatured in
Laemmli buffer, resolved by SDS–PAGE and transferred to PVDF
membranes. Membranes were blocked in PBS/0.1% Tween/10%
nonfat dry milk (NFDM) and incubated with primary antibodies
for 1h to overnight in PBS/0.1% Tween/1% NFDM. Filters were
washed, incubated with HRP-conjugated secondary antibodies,
then rewashed extensively in PBS/0.1% Tween. Detection used the
ECL Lightning Plus reagent from Amersham, Inc., Piscataway, NJ,
USA. The following antibodies were obtained from Cell Signalling,
Beverly, MA, USA, and used according to the manufacturer’s
directions; EGFR, ErbB2, phospho-EGFR-Y845, phospho-EGFR-
Y1068, phospho-ERK1/2, phospho-AKT, AKT, phospho-RPS6,
RPS6, 4EBP1 and eIF4E. Anti-ERK antibody was obtained from
Promega, Inc., Madison, WI, USA, while the anti-HA (Y11), ErbB3
and ErbB4 antibodies were from Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA. The mouse monoclonal 11E12, directed
against the VHL C-terminus, was a kind gift from Dr RD Burk.
Polysome fractionation on sucrose gradients
Cultured cells treated for 2h with inhibitors or vehicle were
incubated for 5min in medium containing 0.1mgml
 1 cyclohexi-
mide (CHX). Adherent cells were washed three times with ice-cold
PBS/0.1mgml
 1 CHX, and harvested with trypsin/0.1mgml
 1
CHX. The cell pellet was lysed for 10min on ice in 500ml of 0.3 M
NaCl/15mM Tris-HCl pH 7.5/15mM MgCl2/1% Triton X-100/
0.1mgml
 1 CHX and 1mgml
 1 heparin. Following centrifugation
(10K, 5min at 41C), the clarified supernatant was layered onto a
10–50% sucrose step-gradient prepared the night before containing
300mM NaCl, 15mM Tris-HCl, pH 7.5, 15mM MgCl2, 1mgml
 1
heparin and 0.1mgml
 1 CHX. Gradients were centrifuged at 37K
RPM for 2.5h in an SW41 rotor, collected from the top using an
ISCO tube piercing device (ISCO, Inc., Lincoln, NE, USA) and
fractions monitored by absorbance at 280nm. RNA was recovered
using sequential guanidine-HCl extraction and ethanol precipita-
tion followed by further purification on RNeasy columns (Qiagen,
Inc., Alameda, CA, USA) and on-column digestion with RNase-free
DNase using conditions recommended by the manufacturer.
RESULTS
Epidermal growth factor receptor expression and
synergistic growth inhibition by Iressa plus rapamycin
Previous reports have shown that EGFR expression is elevated in
RCC although there is less information concerning other ErbB
family members. To address this question, we used real-time RT–
PCR to measure EGFR, ErbB-2, ErbB-3 and ErbB-4 mRNA levels in
14 RCC cell lines (Table 2), genetically verified to be of independent
origin (see Methods). Expression was normalised to the house-
keeping gene, GAPDH, although equivalent results were obtained
using b-actin (not shown). The results demonstrate that EGFR is
the predominantly expressed ErbB family member. Although ErbB-
3 was next most highly and frequently expressed, these levels were
low in comparison to EGFR. In addition, we determined the VHL
mutant status for most of the cell lines and the level of expression
for lines with wt-VHL (Table 2). For comparison, VHL mRNA
levels were 6.7% of GAPDH in the immortalised renal epithelial cell
line, HEK293 (not shown). It is apparent that most lines have either
mutant VHL or express this gene at low levels making any potential
correlations between VHL and EGFR problematic. Corresponding
EGFR protein levels for some of these cell lines are shown in
Figure 1A. There was no consistent relationship between EGFR
mRNA and protein levels (e.g. SKRC-45 and KRCY). These results
suggest that there must be post-transcriptional differences affecting
EGFR in RCC. The other three ErbB family members were not
detectable by Western analysis.
The quantitative EGFR results suggested that a selective
inhibitor, such as Iressa (Gefitinib, ZD1839), might inhibit growth
especially when combined with rapamycin. We tested this
hypothesis initially using the paired cell lines, WT8 and PRC3.
Table 1 Clinical characteristics and von Hippel–Lindau (VHL) status of 12 RCC tumours
Tumour Dx Other features T stage Furhman grade % tumour VHL status Specific alteration
1 Clear cell 1b 2 100 mut N78S
2 Clear cell 2 3 100 mut V155E or L
3 Clear cell 1b 2 100 mut V155E or L
4 Clear cell 3a 2 100 WT
5 Clear cell 1b 2 100 mut L158Q
6 Clear cell 3a 3 100 mut L158P
7 Clear cell 3a 4 90 mut V155E or L
8 Clear cell 3a 4 60 WT
9 Clear cell 1a 2 20 WT
10 Clear cell Cystic 1a 2 20 mut W88C
11 Clear cell Cystic 1b 2 30 mut L128H
12 Clear cell Sarcomatoid 3b 4 100 WT
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sTable 2 Expression
a of ErbB family genes and von Hippel–Lindau (VHL) mutant status in renal cell carcinoma (RCC) cell lines
Sample EGFR ErbB-2 ErbB-3 ErbB-4 VHL mutation VHL exp.
PV10 0.3 0 0.003 0 ND
b
KRCY 0.6 0 0.028 0 Wt 0.3
SKRC39 0.8 0.018 0.009 0.030 Wt 1.2
KV6 1.8 0 0.0004 0 Wt 0.01
A498 2.0 0 0.002 0.002 V142/D143-f.s.
c
ACHN 2.2 0.002 0.142 0 Wt
d 0.2
SKRC48 4.3 0 0.006 0.001 L135-f.s.
SKRC12 4.5 0 0.009 0 N121Y
CAKI2 4.7 0.002 0.309 0 ND
A704 5.8 0.001 0.303 0 ND
SKRC17 6.3 0.003 0.002 0.001 S68-4stop
SKRC02 8.0 0.001 0.001 0 S68P
PRC3 9.3 0.002 0.002 0.010 DG104-f.s.
SKRC45 15.1 0.005 0.059 0 R82P
aExpressed as % of GAPDH.
bNot determined.
cf.s.¼frameshift.
dDiffers from lit report.
12 3 4 5 67 8 91 0
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Figure 1 Differential EGFR levels and ERK phosphorylation in RCC cells. (A) Aliquots (10mg) of cell lysates were analysed by Western blot for levels of
EGFR protein. PRC3, MPR6 and WT8 are derived from 786-O cells by transfection of empty vector (PRC3) or independent wild-type VHL expression
constructs (MPR6 and WT8). Tubulin served as a loading control. (B) RCC cell lines WT8
VHL-wt and PRC3
VHL-mut were grown until 50% confluent, then
treated for 2h with DMSO (lanes 1 and 5), rapamycin (10nM; lanes 2 and 6), Iressa (10mM; lanes 3 and 7) or both (lanes 4 and 8). Aliquots were analysed for
the indicated total and phospho-proteins. (C)W T 8
VHL-wt and PRC3
VHL-mut cells at 50% confluency were treated for 2h with decreasing doses of Iressa
(10–0.1mM) and analysed as above. (D) WT8
VHL-wt cells at 50% confluency were treated for 20h with 10 or 100mM CoCl2, or not, as indicated (Co:). For
the last 2h, selected cultures were treated with rapamycin (10nM), Iressa (10mM) or both; control cells were treated with DMSO. Cells were washed twice
with PBS, harvested and analysed with the indicated antibodies. One lane of PRC3
VHL-mut lysate was included as a positive control for the HIF2a antibody
(arrow). This lane was not analysed with the other four antibodies.
RCC inhibited by Iressa and Rapamycin
RM Gemmill et al
2269
British Journal of Cancer (2005) 92(12), 2266–2277 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sThese lines were derived from 786-O, a clear-cell carcinoma that
contains a deletion and frameshift of the VHL gene (Iliopoulos
et al, 1995). WT8 cells contain stably transfected, HA-tagged VHL
(p24 form), while PRC3 cells contain the vector-only control. Low-
density cultures of WT8 and PRC3 cells were treated with varying
concentrations of Iressa, rapamycin or the combination. After 5
days, growth was measured by MTT assays and the results
converted to a combination index using CALCUSYN (Chou and
Talalay, 1984). Values much less than 1.0 indicate synergy while
values much greater than 1.0 are indicative of antagonism. As
shown in Figure 2, Iressa plus rapamycin at various doses
synergistically inhibited growth of WT8 cells. Nearly identical
results were obtained using an independent stable VHL transfec-
tant, MPR6 (Schoenfeld et al, 1998). These results include Iressa
concentrations within the reported IC50 range for EGFR (i.e. 30–
50nM). At high Iressa and low rapamycin concentrations, a
combination index close to 1.0 was obtained (indicating no
interaction). In contrast, in the VHL-mutant cell lines 786-O and
PRC3, low concentrations of Iressa plus rapamycin were anta-
gonistic. Thus, the introduction of a wt-VHL gene into 786-O cells
confers sensitivity (synergy) to the combination of EGFR plus
mTOR inhibition at low drug concentrations. Of note, the levels of
rapamycin used are readily achievable in patients.
Biochemical correlates of Iressa and rapamycin exposure
To explore the difference in growth inhibition, we examined
selected biochemical targets of EGFR and mTOR signalling in the
PRC3 and WT8 cell lines. Short-term (2h) treatment with Iressa
inhibited phosphorylation of ERK1/2 in WT8 but not in PRC3 cells
(Figure 1B). Iressa had no effect on AKT or 4E-BP1 phosphoryla-
tion in either cell line. Rapamycin, on the other hand, inhibited
phosphorylation of both RPS6 and 4E-BP1 in a VHL-independent
manner. Thus, in these paired cell lines, we identified biochemical
changes that correlated with the observed synergistic growth
inhibition in the MTT assays. Since higher concentrations of Iressa
(10mM) were used in these short-term studies, we performed a
dose–response analysis of ERK1/2 phosphorylation (Figure 1C).
Inhibition was seen in WT8 cells at the lowest Iressa dose used
(100nM) while no inhibition was detected in PRC3.
Differential sensitivity to Iressa in WT8 cells could result from
the absence of HIFa, a consequence of re-expressing wild-type
VHL. As an initial assessment of HIF dependence, we treated WT8
cells with cobalt chloride to chemically induce an hypoxic state
and thus upregulate HIF. Cobalt-treated cells were then tested for
changes in response to Iressa (Figure 1D). Treatment with 10 and
100mM CoCl2 induced similar levels of the 118kDa HIF2a, the only
HIFa isoform expressed in 786-O cells (Iliopoulos et al, 1995).
Induction of HIF2a had no effect on the ability of Iressa to inhibit
Erk phosphorylation (compare lanes 3, 7 and 11), suggesting that
under these conditions, differential sensitivity was not HIF
dependent.
We expanded the biochemical analysis to six additional RCC cell
lines (Figure 3). In the wt-VHL lines, ACHN and KRCY, Iressa
inhibited both ERK1/2 and RPS6 phosphorylation while phospho-
AKT levels were unaffected. In SKRC-39, which expressed the
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Figure 2 Growth inhibition by Iressa and rapamycin in derivatives of 786-O cells. The parental RCC line 786-O and three stably transfected derivatives
were tested for the effects of varying doses of Iressa and rapamycin on growth using MTT assays. MTT absorbance values from single and combined agents
were converted to the combination index (see Methods).
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shighest level of wt-VHL, the basal protein patterns were strikingly
different. These cells overexpressed eIF4E and had low to
undetectable levels of phospho-ERK1/2 (Figure 3). Epidermal
growth factor receptor levels were also substantially reduced
(Figure 1A). Among the three mutant VHL cell lines, only SKRC-45
showed any response to Iressa, consisting of a partial reduction
of ERK1/2 and RPS6 phosphorylation. Rapamycin uniformly
inhibited phospho-RPS6 regardless of the VHL status. In
summary, Iressa was substantially more effective at inhibiting
ERK and RPS6 phosphorylation in RCC cell lines with wt-VHL.
Using a Wilcoxon Rank Sum Test, this approached but did not
reach statistical significance (P¼0.08) because of the limited
number of cell lines.
EGFR protein levels, phosphorylation and polysome
loading of mRNA
Based on the differential responses to EGFR blockade, we
examined levels of EGFR protein in PRC3 and WT8 cells following
treatment with Iressa or rapamycin (Figure 4A). Epidermal growth
factor receptor levels were higher in the VHL mutant, PRC3,
although no changes were induced by treatment. These differences
were more apparent at shorter exposures (compare Figures 1A–
4A). To examine the phosphorylation dynamics of EGFR, we
serum-starved WT8 and PRC3 cells for 2h, then added back serum
plus EGF. Protein lysates were examined at multiple time points
using phospho-specific EGFR antibodies (Figure 4B). In these
experiments, more protein was loaded for WT8 to compensate for
the lower levels of total EGFR. For tyrosine 845, maximum
phosphorylation was seen at 10min in WT8 cells compared to
60min in PRC3. For tyrosine 1068, the onset of maximum
phosphorylation was similar. For both sites, the duration of
phosphorylation was prolonged in PRC3. Similar results were
obtained in an independent experiment carried out to 180min
after EGF addition with evidence of persistent phosphorylation in
PRC3 (not shown). Despite these differences, prior exposure of
both cell lines to Iressa for 15min blocked tyrosine phosphoryla-
tion (not shown). Thus, while the presence of wt-VHL in these
paired cell lines appears to affect EGFR protein levels and
activation, the results do not explain the differential sensitivity
to Iressa. One likely possibility is that VHL mutations upregulate
signalling from other kinases.
To determine whether the elevated EGFR protein in PRC3 was
the result of mRNA differences, possibly due to clonal variation,
we examined message levels by real-time RT–PCR in parental 786-
VHL:
1 2 3 4 5 6 7 8 91 01 11 21 3 1 41 51 61 71 81 92 02 12 22 32 4
S68P S68-stop wt R82P wt wt
Tubulin
eIF4E
RPS6
P-RPS6S235/236
Erk1,2
P-Erk1,2T202/Y204
Akt
P-AktS473
Rap:
Ir:
+ +
+
+
+
+
+
+
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+++
+
++++
+ + + + + +
SKRC-02 SKRC-17 SKRC-39 SKRC-45 ACHN KRCY
Figure 3 Phospho-protein analysis in additional RCC cell lines. Six RCC cell lines were grown to 50% confluency, then treated for 2h with DMSO (lanes
1, 5, 9, 13, 17 and 21), rapamycin (10nM; lanes 2, 6, 10, 14, 18 and 22), Iressa (10mM; lanes 3, 7, 11, 15, 19 and 23) or both (lanes 4, 8, 12, 16, 20 and 24).
Lysates were analysed as in Figure 1. VHL mutational status is indicated along the bottom.
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Figure 4 Total and phospho-EGFR levels in PRC3 and WT8. (A)
Protein lysates, as described in Figure 1, were analysed for total EGFR
protein. The blot was stripped and reprobed with anti-VHL and anti-HA
antibodies. (B) PRC3 and WT8 cultures were grown to 50% confluency,
washed with PBS, then starved in 0.1% serum for 2h. Cells were harvested
at the indicated time points (min) after the addition of 10% serum and
50ngml
 1 EGF. More total protein was loaded in the WT8 lanes to
compensate for the lower amounts of EGFR in this cell line. Otherwise,
equal protein aliquots were analysed for the phosphorylation levels of
tyrosine 845 and 1068 using phospho-specific antibodies.
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sO, PRC3 and WT8 cells. The analyses, performed in triplicate,
demonstrated that there were no differences among the cell lines
(Table 3). Like the original series of RCCs examined, ErbB-2, ErbB-
3 and ErbB-4 mRNA levels were barely detectable and correspon-
ding proteins were undetectable by Western analysis. In contrast,
VEGF expression, as expected, was higher in the VHL mutants
786-O and PRC3 than WT8. These results indicate that the
observed differences in EGFR protein levels are post-transcriptional,
possibly involving protein translation initiation or degradation.
To examine the question of protein translation initiation, we
isolated polysome fractions from WT8 and PRC3 cells and
analysed these by quantitative real-time RT–PCR (Figure 5). No
reproducible differences were identified in ribosome-bound EGFR
mRNA between these cell lines. Furthermore, short-term treatment
with rapamycin or Iressa had no consistent effects on polysome-
associated EGFR message (not shown). These results suggest that
the difference in EGFR protein levels (and phosphorylation
duration) between PRC3 and WT8 involves internalisation or
degradation.
Downregulation of MYC polysome loading by PI3K
inhibition
Activated AKT is known to play an important antiapoptotic role
and also positively regulates protein translation initiation. As
noted above, EGFR and mTOR inhibitors did not affect phospho-
AKT levels and did not have a major effect on EGFR polysome
loading. We wished to determine, therefore, whether short-term
blockade of AKT (using the PI3K inhibitor LY-294002) would have
a demonstrable effect. We chose to focus on MYC translation
initiation (polysome loading) in WT8 cells, since this gene is
upregulated in RCC and because MYC mRNA contains an internal
ribosome entry site, which provides a potential eIF4E-independent
means of translation initiation (Shi et al, 2005). Also, since WT8
cells were more responsive to Iressa and rapamycin, we combined
LY-294002 with these agents. As shown in Table 4, neither Iressa,
rapamycin nor the combination substantially reduced MYC mRNA
ribosome association and these agents may even have increased
polysome loading in some fractions. As a control, we included
RPS19 that contains a 50-untranslated polypyrimidine stretch
known to be sensitive to mTOR inhibition (Meyuhas, 2000). RPS19
loading was substantially reduced in all ribosome fractions by both
agents. In contrast, MYC polysome loading was reduced only by
LY-294002. This effect appeared to be somewhat greater when LY-
294002 was combined with rapamycin or rapamycin plus Iressa.
Analysis of primary RCCs
Cell lines differ from primary tumours in terms of growth rates,
altered microenvironment (nutrients, oxygen tension and extra-
cellular matrix) and the absence of interacting stroma. To test
for differences in phosphoprotein levels, we examined 12 clear-
cell carcinomas and their corresponding uninvolved kidney
(Figure 6). Table 1 (Methods) provides the clinical characteristics
of these tumours including mutational analysis of VHL, which is
Table 3 Expression
a of ErbB family genes in 786-O cell lines
Line EGFR ErbB-2 ErbB-3 ErbB-4 VEGF
786-O 2.0 0.0009 0.0003 0.0001 1.1
PRC3 1.6 0.0005 0.0002 0.0005 0.8
WT8 2.3 0.0005 0.0005 0.0003 0.3
aExpressed as % of b-actin. EGFR¼epidermal growth factor receptor; VEGF¼vas-
cular endothelial growth factor.
60S ribosome
80S ribosome
1–2 ribosome
3–4 ribosome > / = 5 ribosome
> / = 5 ribosomes
bound mRNAs
bound mRNAs bound mRNAs
40S
ribosome
EGFR polysome loading (% of -actin)
PRC3
WT8
1–2 ribosomes 3–4 ribosomes
6.9 5.7 4.2
6.6 7.3 4.4
Figure 5 Polysome analysis of WT8 cells. WT8 cells were grown to 70% confluency, then treated for 2h with DMSO, rapamycin (10nM), Iressa (10mM)
or both, and harvested for polysome fractionation. A representative A280 fractionation profile is shown along with the fractions pooled and the results from
quantitative RT–PCR analysis.
Table 4 mRNA
a loading on polysomes in WT8 cells
Gene Treatment 1–2 rib 3–4 rib Polyrib
MYC DMSO 0.20 0.16 0.08
Iressa 0.11 0.09 0.09
Rapamycin 0.40 0.23 0.20
Iressa+Rapamycin 0.36 0.47 0.14
MYC DMSO 0.31 0.42 0.24
LY294002 0.05 0.16 0.15
Ly+Rap 0.05 0.07 0.09
Ly+Rap+Iressa 0.03 0.05 0.09
RPS19 DMSO 319.3 117.7 10.6
Iressa 149.0 33.9 4.5
Rapamycin 199.3 32.9 3.3
Iressa+Rapamycin 101.4 52.5 2.6
aExpressed as % b-actin. DMSO¼dimethyl sulphoxide.
RCC inhibited by Iressa and Rapamycin
RM Gemmill et al
2272
British Journal of Cancer (2005) 92(12), 2266–2277 & 2005 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
ssummarised in Figure 6. Phospho-ERK1/2 was readily detectable
and upregulated in nine of the 12 tumours (Figure 6A). Of note,
most of these same tumour samples contained elevated levels of
phospho-AKT. Total AKT, ERK and Coomassie staining are shown
as controls. Compared to the cell lines, longer radiographic
exposures were required to detect phospho-AKT. The difference in
phospho-AKT was confirmed in side-by-side comparisons with
selected tumours and cell lines (Figure 6C), while comparable
levels of phospho-ERK were detected in both cell lines and
tumours.
Levels of eIF4E were generally higher in the matched normal
samples than in the tumours, with the exception of tumour #12
that had substantially increased eIF4E (compare lanes 23 and 24).
Tumour 12 had sarcomatoid features (Table 1), indicating a more
aggressive tumour and correspondingly poorer prognosis (Cheville
et al, 2004). This tumour showed no detectable Erk phosphoryla-
tion despite abundant Erk protein and no detectable EGFR
(Figure 6B). The biochemical characteristics of tumour 12 thus
closely match the cell line SKRC-39 and verify that a subset of
RCCs appear to be activated at this downstream translation
regulatory point.
Most of the tumours expressed more EGFR protein than the
corresponding normal tissue, yet EGFR levels were up to 30-fold
higher in cell lines despite comparable levels of mRNA (Figure 6B,
TN
T N TN T N TN TN TN TN TNTN TN TNTN
TNTNTN TNTN T N T N TNTN TN TN
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Figure 6 Analysis of primary tumours. (A) Protein (10mg) from 12 matched pairs of renal tumours (T) and normal kidney (N) were analysed with the
indicated antibodies on two separate sets of blots. Equivalent gels were stained with Coomassie blue (CBB) for loading. The low protein content of tumour
#10 indicates that relative Erk phosphorylation was even higher than the band intensity suggests. VHL mutational status is summarised by m¼mutant;
w¼wild type. (B) In total, 30mg of tumour and normal lysates were analysed for levels of EGFR, phospho-RPS6 and total RPS6. The four cell line lysates
were treated with Iressa and rapamycin (I/R) for 2h or not ( ). Densitometric analysis for the left panel was normalised to the tumour with the lowest EGFR
signal. Densitometry for the right panel utilised a shorter exposure to remain within the linear response range. Even the longest exposures failed to detect
EGFR in T-12. The asterisk denotes a background band. (C) Direct comparisons of phospho-Erk and phospho-Akt levels in a subset of tumours and cell lines
on the same filter. (D) WT8
VHL-wt cultures starting at 70% confluency (time zero) were grown under standard culture conditions over 48h and periodically
sampled. Phospho-RPS6 levels were downregulated at 100% confluency.
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protein levels that were as high as the cell lines and at least T-6 also
expressed elevated EGFR message. In contrast, ErbB-3 mRNA was
much higher in the primary tumours (and matched normal
kidney) than in RCC cell lines, while ErbB-4 message was markedly
reduced in tumours compared to normal (Table 5).
An additional major difference between tumours and cell lines
involved phospho-RPS6, an indicator of mTOR activity. Phos-
phorylated RPS6 was undetectable in both tumours and normal
kidney (Figure 6B), despite usually abundant levels of total RPS6
protein. Cell–cell contacts in solid tumours may result in
alterations akin to contact inhibition in tissue culture. We
therefore examined the effect of confluency on the phosphoryla-
tion state of RPS6 in WT8 cells (Figure 6D). While phospho-Akt
and phospho-Erk were unaffected, phosphorylation of RPS6 on
Ser235/236 was dramatically downregulated at 100% confluency.
Thus, differences in RPS6 phosphorylation between tumours and
cell lines may be a result of different growth rates or of cell–cell
interaction.
DISCUSSION
The results reported here demonstrate that combined inhibition
of EGFR and mTOR provides a more effective growth blockade
in RCC cell lines than either agent alone. Moreover, this effect was
influenced by the mutational state of VHL. While we observed
synergistic growth inhibition in both mutant and wt-VHL cell lines
at high drug concentrations, synergy at Iressa doses near the IC50
for EGFR were limited to wt-VHL cells. Western blot analysis of
phospho-proteins demonstrated that EGFR inhibition selectively
blocked phosphorylation of ERK1/2 and RPS6 in cells with wt-
VHL. The inhibition of RPS6 phosphorylation by Iressa, however,
was not universal, which may relate to the presence of a PTEN
mutation in 786-O and its derivatives (Kau et al, 2003). Mutant
VHL lines showed little response to Iressa in terms of ERK and
RPS6 phosphorylation and AKT phosphorylation was unaffected
by either agent irrespective of VHL. These results indicate that
wt-VHL cells are more sensitive to EGFR inhibition (or more
dependent upon EGFR signalling for growth) than their mutant
counterparts. Induction of HIF2a using cobalt treatments failed to
prevent Iressa inhibition of Erk phosphorylation in WT8
VHL-wt
cells, suggesting that this effect is independent of HIF.
Perera et al (2000) also noted that wt-VHL conveyed sensitivity
to the EGFR blocking antibody, C225. However, changes in
phospho-protein signalling were not described. Interestingly, we
observed that the combination of low-dose Iressa and rapamycin
was antagonistic in cells with mutant-VHL. This raises the
possibility that certain drug targets might be regulated in an
opposite manner depending on the state of VHL. Similar AKT-
dependent results have been reported for single-agent rapamycin
(Gera et al, 2004). However, since we did not detect changes in
AKT phosphorylation, another target(s) that is VHL-dependent
presumably would be responsible. Our studies suggest that there
are at least three biochemical patterns in RCC cell lines: those
responsive to EGFR inhibition in terms of ERK and RPS6
phosphorylation, those that are resistant and a third subset (likely
resistant) with overexpression of eIF4E and downregulation of
upstream signalling components. Of note, in cells where the eIF4E-
binding protein 4E-BP1 is limiting, eIF4E overexpression also
drives translation initiation in a rapamycin-resistant manner
(Dilling et al, 2002).
During these investigations, we identified higher levels of EGFR
protein in PRC3 cells (mutant VHL) compared to WT8. In
agreement, EGFR phosphorylation following EGF stimulation was
also prolonged. However, this appears not to be the explanation for
differential Iressa sensitivity since pretreatment of cells with Iressa
blocked EGFR phosphorylation equally. Also, EGFR protein levels
were not affected by Iressa or rapamycin. We also noted that EGFR
protein was generally higher in cell lines than primary tumours
despite comparable mRNA levels. Whether this represents an in
vitro selection phenomenon with preferential growth of these cells
is unknown. Previous investigators have not reported suppression
of EGFR protein after re-expression of wt-VHL (Knebelmann et al,
1998; Gunaratnam et al, 2003). However, in the report by
Gunaratnam et al, (2003), adenovirus-mediated introduction of
wt-VHL into 786-O cells visibly reduced EGFR levels (see their
Figure 2A), although this difference was either discounted or not
further clarified (Gunaratnam et al, 2003). In the report of
Knebelmann et al, (1998), the Western blot appears too over-
exposed for optimal quantitation (Knebelmann et al, 1998). On the
other hand, we have not detected reduced EGFR protein in MPR6,
an independent wt-VHL derivative of 786-O. However, MPR6
expresses two anti-VHL reactive bands at considerably lower levels
than the single band detected (with either anti-HA or anti-VHL
antibodies) in WT8. Thus, we cannot conclude that the changes in
EGFR are a consequence of VHL. This difference could, for
example, be explained by an acquired clonal variation affecting
some aspect of EGFR protein processing or degradation. In any
case, since EGFR mRNA levels in 786-O, PRC3 and WT8 were
essentially identical, and since we were unable to detect consistent
differences in EGFR ribosome association between PRC3 and WT8,
we suspect that the difference involves EGFR degradation, which
would be consistent with the observed differences in the duration
of receptor phosphorylation. This would also be consistent with
the absence of EGFR mRNA among a set of messages whose
translation initiation was affected by VHL mutation (Galban et al,
2003).
EGFR overexpression in RCC has previously been well
documented (Gomella et al, 1989; Uhlman et al, 1995). The
finding that TGFa is constitutively expressed as a consequence of
VHL mutations (de Paulsen et al, 2001), and that TGFa is a
mitogen for renal epithelial cells, considerably strengthened the
hypothesis that EGFR signalling is important in RCC development.
However, in contrast to lung cancer, activating mutations in exons
19 and 21 of EGFR were not detected in 16 kidney tumours (Lynch
et al, 2004) and, clinically, tumour regressions following EGFR
inhibition have been minimal (Amato, 2005). If EGFR signalling is
deregulated in RCC, then why are clinical responses so limited?
Possible explanations include involvement of additional ErbB
family members not affected by selective EGFR inhibitors,
activation of other growth factor pathways such that EGFR
blockade is insufficient to induce tumour regression, and changes
in apoptotic components that prevent cell death in response to
EGFR blockade.
Table 5 Expression
a of mRNA for ErbB Genes in renal cell carcinoma
(RCC) tumours
Sample EGFR ErbB-2 ErbB-3 ErbB-4
1-N 5.5 0.04 3.2 14.8
2-N 1.7 0.01 3.0 2.4
3-N 1.8 0.01 3.0 1.3
4-N 1.3 0.01 1.8 5.7
5-N 1.7 0.01 2.8 1.6
6-N 5.5 0.03 1.7 1.6
1-T 2.7 0.002 1.0 0.0003
2-T 1.9 0.002 2.2 0.001
3-T 1.9 0.001 1.9 0.005
4-T 3.1 0.002 0.6 0.017
5-T 2.5 0.001 0.4 0.020
6-T 13.2 0.004 2.8 0.035
aExpressed as % of GAPDH. EGFR¼epidermal growth factor receptor; N¼normal
adjacent kidney; T¼tumour.
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that EGFR was by far the predominant component among mRNAs
and the only ErbB protein detectable by Western analysis. For
ErbB-2, previous reports have been inconsistent. Stumm et al
(1996) reported that p185erbB-2 was overexpressed in RCC while
Freeman et al, (1989) found ErbB-2 to be reduced (Freeman et al,
1989; Stumm et al, 1996). We found ErbB-2 mRNA was expressed
at low levels in both cell lines and primary tumours. For ErbB-3
and ErbB-4, Thomasson et al (2004) reported that both receptors
were downregulated. Our results are in agreement for ErbB-4,
although ErbB-3 was discordant, being downregulated in cell lines
but maintained at substantial levels in primary tumours.
Potentially, this is an important difference although the biological
consequences are unclear. Although ErbB-3 lacks kinase activity
(Burgess et al, 2003), it couples efficiently to phosphatidylinositol
3-kinase (Fedi et al, 1994; Burgess et al, 2003), has distinct
preferred ligands (i.e. NDF, HB-EGF and BTC)(Beerli and Hynes,
1996) and is endocytosed less readily than EGFR (Baulida et al,
1996). Interestingly, in mice one of these ligands, NDF, is most
highly expressed in the kidney and during development correlates
with urogenital organ formation (Castagnino et al, 2000). At least
in keratinocytes, NDF is induced by hepatocyte growth factor
(HGF) (Castagnino et al, 2000). If this occurred in the kidney, then
RCCs with VHL mutations, which are known to upregulate MET
and be hyper-responsive to HGF (Oh et al, 2002; Koochekpour
et al, 1999), might behave differently in terms of ErbB signalling
and EGFR inhibition than cell lines.
Regarding other growth factor pathways that might render
EGFR blockade insufficient, we note that phospho-AKT was not
affected by short-term Iressa, rapamycin or the combination.
Similarly, phospho-ERK1/2 showed no response to Iressa in
mutant VHL cell lines. These results strongly suggest that other
growth factor signalling pathways are activated. The inability of
Iressa and rapamycin to affect AKT led us to ask whether blocking
AKT activation with the PI3K, LY294002, would alter protein
translation initiation of MYC. We chose MYC because of its
overexpression in RCC (Yao et al, 1988) and because it contains
an internal ribosome entry site that may allow initiation in an
eIF4E-independent manner. MYC mRNA polysome loading was
not affected by Iressa or rapamycin while the control RPS19 was
substantially downregulated. In contrast, a strong reduction in
MYC polysome loading was achieved by 2h PI3K inhibition.
Lastly, how relevant are the phospho-protein analyses to
primary tumours? Levels of phospho-ERK1/2 were similar between
cell lines and primary tumours and these same tumours also had
elevated phospho-AKT, although less so than in cell lines. Thus,
phospho-ERK and AKT may be useful biomarkers in RCC. While
most tumours overexpressed EGFR compared to matched normal
controls, only two of 12 contained EGFR levels comparable to
those observed in RCC cell lines. Another striking difference was
the absence of RPS6 phosphorylation in any of the tumour/normal
samples despite easily detectable total RPS6 protein. RPS6 is
phosphorylated by p70S6K, which in turn is activated by mTOR
(Hay and Sonenberg, 2004). Similar results were suggested by
Kenerson et al (2002) who found increased phospho-RPS6 in RCCs
derived from patients with tuberous sclerosis but not in sporadic
RCCs (Kenerson et al, 2002). Other studies of non-RCC primary
tumours have frequently identified mTOR activation. A broad
study of phosphorylated S6K1 in eight common tumour types
found nearly all with some reactivity while intense staining (3þ)
was present in up to 60% of colon adenocarcinomas and nearly
50% of lymphomas, ovarian, melanoma, lung and brain tumours
(Xu et al, 2004).
Our results suggest that mTOR may be relatively inactive in
primary RCCs. However, there are two important caveats. The first
is that mTOR activity could be confined to areas of growth or
invasion that would have been missed by our examination of bulk
tumour protein. This interpretation is strengthened by our
observation that confluency dramatically affected phospho-RPS6
levels in WT8 cells. Alternatively, mTOR may be activated in only a
subset of RCCs in agreement with the observed 7% response rate to
CCI-779 (Atkins et al, 2004).
One cell line (SKRC-39) expressed high levels of eIF4E in the
absence of upstream signalling, and one tumour (#12) showed a
very similar biochemical pattern, with high eIF4E but no detectable
EGFR or phospho-Erk. Interestingly, this tumour had sarcomatoid
differentiation, an indicator of more aggressive behaviour and
poor prognosis (Cheville et al, 2004). Thus, eIF4E overexpression
appears to define a subset of RCCs that are likely to be resistant to
rapamycin and/or Iressa, consistent with the aggressive nature of
sarcomatoid RCCs.
In summary, our results provide rationale for the testing of
combined EGFR and mTOR inhibitors, at least in the subset of
RCC patients with wt-VHL. It will be important to determine
whether mTOR activation is heterogeneous or activated in only
certain subsets of tumours and whether in vivo phospho-AKT is
affected by these treatments.
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